| Summary: | Issues in Emerging Health Technologies is a series of concise bulletins describing drug and non-drug technologies that are not yet used (or widely diffused) in Canada; in most cases, Health Canada's approval is anticipated in the next six to 18 months. Bulletins include a description of the emerging technology, patient indications, regulatory status, adverse effects, costs, anticipated diffusion rates, implementation issues, and a discussion of the reliability and quality of available evidence. While the bulletins analyze all available data, the evidence base is generally insufficient to permit a meta-analysis of individual trials or other statistical analyses. Each bulletin is peer-reviewed by two or more external clinical experts
|
|---|